Feng Ye

Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China

Ruchong Chen, Wenhua Liang, Mei Jiang et al. · CHEST Journal · 2020 · 684 citations · Full text

Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

Wei‐jie Guan, Wenhua Liang, Yi Zhao et al. · 2020 · 649 citations · Full text

Composite Endpoint, Covid-19 Epidemiology, Covid-19 +17

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer

Feng Ye, Guanfeng Gao, Yutian Zou et al. · Molecular Therapy — Nucleic Acids · 2019 · 256 citations · Full text

Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

Shun Lü, Lin Wu, Hong Jian et al. · The Lancet Oncology · 2022 · 227 citations

Oncology, First Interim Results, Bevacizumab Biosimilar Ibi305 +10